World TB Day: a chance to reflect on the future
This article was originally published in Scrip
We all know about the risks of new drug development and the cost barriers to patient access to those products when they are approved. These problems are particularly acute where antibacterials are concerned, as resistance grows to even some of the most commonly used drugs, all the more so in developing countries where infectious disease takes a disproportionate toll.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.